Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 2 |
2022 | 2 |
2023 | 1 |
2024 | 1 |
Search Results
5 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Corrigendum to "Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study" [Vaccine: X 11 (2022) 100189].
Vaccine X. 2023 Aug;14:100307. doi: 10.1016/j.jvacx.2023.100307. Epub 2023 Apr 28.
Vaccine X. 2023.
PMID: 37131960
Free PMC article.
Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study.
Sáez-Llorens X, Lanata C, Aranguren E, Celis CR, Cornejo R, DeAntonio R, Ecker L, Garrido D, Gil AI, Gonzales M, Hess-Holtz M, Leroux-Roels G, Junker H, Kays SK, Koch SD, Lazzaro S, Mann P, Quintini G, Srivastava B, Vahrenhorst D, von Eisenhart-Rothe P, Wolz OO, Oostvogels L.
Sáez-Llorens X, et al. Among authors: vahrenhorst d.
Vaccine X. 2022 Aug;11:100189. doi: 10.1016/j.jvacx.2022.100189. Epub 2022 Jul 1.
Vaccine X. 2022.
PMID: 35791320
Free PMC article.
Item in Clipboard
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial.
Kremsner PG, Mann P, Kroidl A, Leroux-Roels I, Schindler C, Gabor JJ, Schunk M, Leroux-Roels G, Bosch JJ, Fendel R, Kreidenweiss A, Velavan TP, Fotin-Mleczek M, Mueller SO, Quintini G, Schönborn-Kellenberger O, Vahrenhorst D, Verstraeten T, Alves de Mesquita M, Walz L, Wolz OO, Oostvogels L; CV-NCOV-001 Study Group.
Kremsner PG, et al. Among authors: vahrenhorst d.
Wien Klin Wochenschr. 2021 Sep;133(17-18):931-941. doi: 10.1007/s00508-021-01922-y. Epub 2021 Aug 10.
Wien Klin Wochenschr. 2021.
PMID: 34378087
Free PMC article.
Clinical Trial.
Item in Clipboard
Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity.
Wolz OO, Vahrenhorst D, Quintini G, Lemberg C, Koch SD, Kays SK, Walz L, Kulkarni N, Fehlings M, Wengenmayer P, Heß J, Oostvogels L, Lazzaro S, von Eisenhart-Rothe P, Mann P.
Wolz OO, et al. Among authors: vahrenhorst d.
Vaccines (Basel). 2024 Apr 6;12(4):388. doi: 10.3390/vaccines12040388.
Vaccines (Basel). 2024.
PMID: 38675770
Free PMC article.
Item in Clipboard
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
Kremsner PG, Ahuad Guerrero RA, Arana-Arri E, Aroca Martinez GJ, Bonten M, Chandler R, Corral G, De Block EJL, Ecker L, Gabor JJ, Garcia Lopez CA, Gonzales L, Granados González MA, Gorini N, Grobusch MP, Hrabar AD, Junker H, Kimura A, Lanata CF, Lehmann C, Leroux-Roels I, Mann P, Martinez-Reséndez MF, Ochoa TJ, Poy CA, Reyes Fentanes MJ, Rivera Mejia LM, Ruiz Herrera VV, Sáez-Llorens X, Schönborn-Kellenberger O, Schunk M, Sierra Garcia A, Vergara I, Verstraeten T, Vico M, Oostvogels L; HERALD Study Group.
Kremsner PG, et al.
Lancet Infect Dis. 2022 Mar;22(3):329-340. doi: 10.1016/S1473-3099(21)00677-0. Epub 2021 Nov 23.
Lancet Infect Dis. 2022.
PMID: 34826381
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite